Oncolytic Virus Cancer Therapy Market Set for Rapid Growth Through 2036

The oncolytic virus cancer therapy market is expected to expand rapidly during 2026–2036, supported by increasing investments in next-generation cancer treatments, advances in viral engineering, and growing clinical development across multiple tumor types. Oncolytic viruses are designed to selectively infect and destroy cancer cells while stimulating broader antitumor immune responses, creating opportunities for innovative approaches in oncology.

DelveInsight’s Oncolytic Virus Cancer Therapy Market Size, Target Population, Competitive Landscape & Market Forecast provides an assessment of the market across the 7MM, comprising the United States, EU4, the United Kingdom, and Japan. The analysis covers historical and forecasted market trends from 2022 to 2036, along with patient populations, emerging therapies, competitive dynamics, and market opportunities.

To know more about oncolytic virus therapies developers companies, visit @ Oncolytic Virus Landscape - https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Oncolytic Virus Cancer Therapy Market Overview and Growth Outlook

The oncolytic virus cancer therapy market was valued at approximately USD 177 million in the 7MM in 2025. The United States represented the largest share of the market during the same year compared with the EU4, the United Kingdom, and Japan.

The market encompasses a broad range of cancer indications, including melanoma, biliary tract cancer, head and neck cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), hepatocellular carcinoma, breast cancer, prostate cancer, brain cancer, bladder cancer, ovarian cancer, and other malignancies.

Oncolytic virus therapies are particularly being investigated for patients with relapsed or refractory disease. Their ability to combine direct tumor-cell destruction with immune stimulation has generated considerable interest among researchers and developers seeking new treatment approaches for advanced cancers.

Rising Adoption of Novel Cancer Immunotherapies

The increasing adoption of immuno-oncology strategies is one of the major factors supporting the growth of the oncolytic virus cancer therapy market. Unlike conventional treatments that primarily target cancer cells through specific cytotoxic mechanisms, oncolytic viruses can potentially create a localized immune response within tumors.

These therapies may selectively infect malignant cells and cause tumor-cell destruction while releasing tumor-associated antigens that can stimulate immune activity. Certain engineered viruses are additionally designed to deliver therapeutic genes or modify the tumor microenvironment, potentially improving immune recognition and treatment effectiveness.

The expanding focus on personalized and targeted cancer treatments is therefore contributing to increased research into oncolytic virus-based therapeutic platforms.

Advances in Viral Engineering and Clinical Development